Amarin Accelerates Timeline For NDA Filing Of AMR101
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.
You may also be interested in...
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.
Amarin Moves Beyond Bridge Financing With $70 Million Private Placement
Existing and new investors are drawn by the potential of a compound that would compete with statins in the dyslipidemia market.